Non-toxic protocol to establish paraoxonase 1 (PON1) status

Introduction Paraoxonase 1 (PON1) is a member of a three-gene family localized on human chromosome 7. Due to its role in the metabolism of both lipids and organophosphorus
(OP) compounds, genetic variability in PON1 has been examined by many research groups as a risk factor for vascular and other diseases as well as for OP exposure. A simple, high throughput, two-substrate assay/analysis system determines both PON1 levels as well as the functional PON1192 allo form(s) present in plasma (PON1 Status). A problem with the current PON1 status analysis is that both substrates are highly toxic OP compounds. Technology description Clement Furlong’s laboratory has invented a protocol for establishing an individual's PON1 status and phenotype without the use of toxic organophosphorus substrates. It is suitable for use in medical technology laboratories for establishing PON1 status that is related to risk for carotid artery disease & other vascular disease, risk of complications from exposure to diazinon and chlorpyrifos, probable risk factor for ALS and for diabetic complications. Business Opportunity The American Association of Poison Control Centers' National Incidence Report indicates that pesticide injuries number 102,754 persons annually. Nationally, 4.2% of poisonings are due to insecticides. Worldwide mortality studies report mortality rates from 3-25%. Intellectual Property Position This technology is available for licensing. Related Publication(s)
Furlong CE, Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds, J Biochem Mol Toxicol. 2007;21(4):197- 205. For more information on this technology contact:
Bolong Cao, Ph.D. Licensing Officer, Invention Licensing bolongc@u.washington.edu 206-685-9348

Type of Offer: Licensing



Next Patent »
« More Life Sciences Patents
« More Medical Patents

Share on      


CrowdSell Your Patent